The introduction of Retatrutide in the UK is generating significant excitement within the obesity community. This innovative dual medication – targeting both GLP-1 and GIP – offers a significantly new solution to combating weight challenges. Until recently, options have been limited for many, and Retatrutide embodies a encouraging prospect for